Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Next Previous
Trial Profile

A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ampreloxetine (Primary)
  • Indications Orthostatic hypotension
  • Focus Registrational; Therapeutic Use
  • Acronyms SEQUOIA
  • Sponsors Theravance Biopharma

Most Recent Events

  • 09 May 2025 According to a Theravance Biopharma media release, additional analysis data from this trial presented at the International MSA Congress.
  • 07 Apr 2025 According to a Theravance Biopharma media release, results form these studies supported registrational study in patients with nOH and MSA, CYPRESS currently ongoing.
  • 07 Apr 2025 According to a Theravance Biopharma media release, new analysis form Study 0169 and Study 170 were presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top